

Caltech/MIT Enterprise Forum  
April 21, 2007

How to Succeed In Starting a New Life Sciences Company  
in the Greater Los Angeles Area

**Keynote Speaker**

**Mark E. Davis, Ph.D.**

*Schlinger Professor of Chemical Engineering*  
California Institute of Technology  
*Co-founder*  
Insert Pharmaceuticals, Inc.

Mark E. Davis is the Warren and Katharine Schlinger Professor of Chemical Engineering at the California Institute of Technology and a member of the Experimental Therapeutics Program of the Comprehensive Cancer Center at the City of Hope. He has over 350 scientific publications, two textbooks and over 50 patents. Professor Davis is a founding editor of *CaTTEch* and has been an associate editor of *Chemistry of Materials* and the *AIChE Journal*. He is the recipient of numerous awards including the Colburn and Professional Progress Awards from the AIChE and the Ipatieff, Langmuir and Murphree Prizes from the ACS. Professor Davis was the first engineer to win the NSF Alan T. Waterman Award. He was elected in the National Academy of Engineering in 1997 and the National Academy of Sciences in 2006. Professor Davis' research efforts involve materials synthesis in two general areas; namely, zeolites and other solids that can be used for molecular recognition and catalysis, and polymers for the delivery of macromolecular therapeutics such as nucleic acids. He is the founder of Insert Therapeutics Inc., a company based in Pasadena, CA USA, focused on the use of cyclodextrin-containing polymers for drug delivery applications ([www.insert.com](http://www.insert.com)) and Calando Pharmaceuticals, Inc. ([www.calandopharma.com](http://www.calandopharma.com)) a company based in Pasadena, CA USA that creates RNAi therapeutics. He is currently or has been a member of the scientific advisory boards of Symyx (Nasdaq: SMMX), Alnylam (Nasdaq: ALNY) and NovoDynamics.

**PANELISTS**

**Kenneth C. Aldrich**

*Managing Director*  
Convergent Ventures  
*Chief Executive Officer*  
International Stem Cell Corp.

Kenneth C. Aldrich, J.D. has more than 25 years of experience as a private equity investor and entrepreneur. He has provided early-stage funding for a variety of biomedical and technology start-ups, both individually and as a manager of various private investment partnerships. Mr. Aldrich is a Managing Member of Convergent Investors, LLC. He is a member of the Board of Directors of Neurion Pharmaceuticals, Inc. and a member of the Business Advisory Board of ORFID Corporation. Through investments prior to the formation of Convergent Ventures, Mr. Aldrich is a founder of WaveTec Vision Systems, an ophthalmic device company and Lifeline Cell Technology, a cell biology company, and its parent corporation, American Stem Cell Corporation. He has also been involved in a variety of other ventures outside the life science area, including his role as a current board member of Next Estate Communications, America's largest provider of prepaid MasterCard and Visa debit cards sold at retail stores. Mr. Aldrich

## PANELISTS *(continued)*

previously served on the management team of the West Coast real estate department of a major investment banking firm, and subsequently as chief financial and legal officer of a public company which he helped to form and build. He practiced law in Dallas, Texas and Los Angeles, California, where he served with the firm of O'Melveny & Myers LLP. He holds a J.D. from Harvard Law School and an A.B. from Harvard University, both with honors.

### **Sheldon Schuster, Ph.D.**

*President*

Keck Graduate Institute

Sheldon Schuster, Ph.D., is currently the President of the Keck Graduate Institute of Applied Life Sciences (KGI) in Claremont, CA. KGI is the newest member of the Claremont College Consortium and features a professional graduate program designed to educate scientists and engineers to be the bioscience business leaders of the 21<sup>st</sup> Century. As a unique professional degree, the MBS emphasizes interdisciplinary and team-based active learning, and is becoming the premier degree for those wishing to enter and lead the biotechnology, medical device, pharmaceutical development and modern agricultural industries. Dr. Schuster has also expanded the program to include a distinctive educational opportunity in bioprocess and operations management that will educate the leaders of this critical component of biosciences commercialization.

Prior to joining KGI, Dr. Schuster was the Interim Assistant Vice President for Research, Director of The Biotechnology Program and Professor of Biochemistry and Molecular Biology at the University of Florida. His research focused on the mechanism of tumor drug resistance, and the rational design of potential anti-tumor therapies based on studies of specific enzyme structures. In addition, he initiated a research program attempting to use novel gene analysis tools to determine the microbial etiology of numerous chronic human diseases. His research work has been funded by the National Cancer Institute and the American Cancer Society and has resulted in over 140 peer-reviewed publications and ten patents. Dr. Schuster is a graduate of the University of California at Davis and earned his Ph.D. from the University of Arizona. He has worked at the Institute for Enzyme Research at the University of Wisconsin and was on the faculty at the University of Nebraska as Professor of Chemistry and Biological Sciences. Dr. Schuster joined the faculty of the University of Florida in 1989, and moved to KGI in 2003. He is active in the development of start-up companies from KGI and the technologies from other universities. Dr. Schuster was one of the founders of Restoragen, Inc. (formerly BioNebraska Inc.), a biotechnology company that produced recombinant peptide therapeutics for the cure of Diabetes and Osteoporosis, and AquaGene, a company developing technologies to produce biopharmaceuticals using fish as the bioreactor.

Dr. Schuster has had a long-standing interest in biotechnology education, and is active nationally and locally promoting development of the workforce necessary to sustain a viable biotechnology sector. He has been active in leadership roles in BIO and the Council for Biotechnology Centers, and is presently Associate Editor for *Biotechnology of the journal Biochemistry and Molecular Biology Education (BAMBED)*. In addition, he has been exploring the best methods to bridge the gap between ongoing basic research in universities and the applied technologies required for commercial development.

## **PANELISTS** *(continued)*

### **David Skinner**

*Vice President and Chief Financial Officer*  
LCS Constructors, Inc.

In 1994, David joined LCS Constructors, Inc. (a nationally renowned general contractors dedicated to laboratories and technical facilities) after working as a CPA for eighteen years. For the last nine years, David has used that expertise as Vice President and Chief Financial and Administrative Officer for LCS. He brings over 25 years of experience in the construction and real estate industries to LCS.

A 1972 University of Texas graduate, David became the Executive Vice President for Fuqua Development, a residential/commercial development and construction firm in Houston . David managed all finance, administration and marketing operations for Fuqua, and was responsible for land acquisitions, advertising and both interim and permanent financing.

After leaving Fuqua, David moved to Mac Haik Enterprises (MHE), a commercial real estate development and investment company, as the Vice President of Finance where he spent four years overseeing their finance and administration. Under David's supervision, MHE built and managed over 1,000,000 square feet of commercial office space. MHE also owned three auto dealerships, chartered a new Savings & Loan and managed the fitness centers in the office complex.

In 1987, Mechanical Specialties International named David Vice President. During the next three years David was responsible for the finance and administration for this design and laboratory facilities contractor.

In a departure from the construction industry, David became the Vice President and General Manager for the Enbee Company. In this role, David was responsible for finance, administration, warehousing and marketing for the largest distributor of promotional products in the Texas Gulf Coast market.

## **MODERATOR**

### **Ira Moskatel**

Attorney  
Arnold & Porter LLP

Ira D. Moskatel, practices law at Arnold & Porter LLP in Los Angeles, where he focuses on the representation of businesses that depend on intellectual property or technology, with emphasis in licensing, mergers and acquisitions, joint ventures and strategic alliances. Ira was a founder of Teradata Corporation, a manufacturer of massive parallel database computers (acquired by AT&T several years after a major public offering) and served as a member of the Board of Directors of Peter Norton Computing, Inc. before its acquisition by Symantec. He is a past chair of the Caltech/MIT Enterprise forum and has served as Chair of the Law and Technology Section of the Los Angeles County Bar Association. He has lectured and written extensively for major publications on legal aspects of technology, electronic commerce and

## **MODERATOR** *(continued)*

data security. Ira received a Bachelor of Science in Engineering and Applied Science from the California Institute of Technology and a J.D. from the University of Southern California Law Center, where he was elected to Order of the Coif and the Board of Editors of the Southern California Law Review.

## **PROGRAM PRODUCERS**

### **Ira Moskatel**

Attorney  
Arnold & Porter LLP

### **Rogelio F. Nochebuena**

*President*  
*Nochebuena R&D*

Nochebuena R&D is a consulting organization based in Pasadena that focus on assisting small companies as well as large enterprises to solve problems in a cost-effective way in the fields of lasers and nanotechnology.

Mr. Nochebuena has more than 20 years of experience in high technology. He has worked in Fortune 100 companies, as well as start-ups. Some of the companies that he has worked for include Agilent Technologies, Xerox Corp, and Carl Zeiss where he served in senior technical and marketing positions. His consulting practice includes clients such as Lawrence-Livermore National Labs, Intelligent Optical Systems as well as tier one universities.

He has developed an ability to spot technologies in the embryonic stages and advise entrepreneurs and venture capital clients on how best to harvest such developments. Recently he was appointed as Executive-in-Residence at Angel Strategies, where he reviews investments in the medical device and biotechnology industries.

Mr. Nochebuena combines knowledge in the physical and biological sciences and has been involved in a variety of projects with strong emphasis on lasers and opto-electronic materials and devices. While working at world famous Xerox PARC, he was tutored in nanotechnology by Professor Cal Quate, the co-inventor of the Atomic Force Microscope. Since then he has been involved in a variety of projects that include nanolaminates, organic nanotubes, OLED's (Organic Light Emitting Diodes), and avant- garde photovoltaics.

He brings expertise in the areas of technology transfer, commercialization and licensing IP, managing innovation and business strategy.

He has participated in a number of panels and local seminars and conferences, and held the position of Chapter Vice-Chair for the IEEE Laser and Opto-Electronics Society.

His education includes graduate work in Electrical Engineering and Material Science from Brigham Young University and Rice University, and holds an MBA from Pepperdine University.

# CHRISTIE | PARKER | HALE LLP

Leaders in Intellectual Property Law & Complex Litigation

For more than five decades Christie, Parker & Hale (CPH) has rigorously protected the discoveries and inventions of their clients. They have watched Pasadena grow, Southern California blossom, and their own intellectual property practice surge forward to meet new challenges here and abroad.

Unlike general practice firms, CPH's practice is rooted in intellectual property. With breadth and depth of expertise, experience, judgment and creativity they specialize in patents, trademarks, copyrights, trade secrets, unfair competition, plant variety protection, related litigation, and international property rights.

Realizing the full potential of a client's business is their primary goal. They can best serve their clients-by developing long-term partnerships. Some of their most successful clients first came to them while still experimenting in their garages. Working hand-in-hand with them – CPH has obtained their first patent, guided them through their initial developments and watched them achieve market leadership.

Anticipating clients' needs, CPH provides practical, cost-effective advice. They create value in their services by thorough analysis, experienced judgment, and innovative approaches concerning:

- 1) The profitable exploitation of intellectual property
- 2) Controlling the costs of creating and protecting intellectual property
- 3) Licensing intellectual property
- 4) Creating and protecting intellectual property in foreign markets
- 5) Dealing with encroachment on intellectual property rights

In the tradition of their founders, all of the firm's patent attorneys hold degrees in some field of science or engineering including advanced degrees in biotechnology, computer science, electronics, mechanics, material sciences, chemistry, and medical technology. Their attorneys effectively handle subject matter in all fields of technology. Teaming seasoned litigators with technically versed patent prosecutors is one of their greatest strengths for successfully handling litigation and related issues.